Salt Composition
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Used In
Treatment of Coronavirus disease (COVID-19)
Customers also bought
More About Codifab Tablet
Benefits
In Treatment of Coronavirus disease (COVID-19) Coronavirus disease (Covid-19) is a highly infectious disease that is caused by a strain of a virus called coronavirus. The most common symptoms are fever, cough, loss of taste or smell, breathing difficulty, nasal congestion, and diarrhea among others. Codifab Tablet is used to manage these symptoms in mildly to moderately infected individuals and helps you recover from the infection. Codifab Tablet should be taken only if prescribed by a doctor. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Codifab Tablet can be taken it with or without food, although it's advisable to take it consistently at the same time.
How it works
Codifab Tablet is an antiviral medicine. It stops the SARS-Co V-2 virus from multiplying. By doing so, it decreases viral load in the body, restricts the spread of infection and helps in speeding up the recovery process.
Consult your Doctor: Please consult your doctor regarding the safety of consuming alcohol with Codifab Tablet . Experts have not found evidence of alcohol impairing the effectiveness of the medicine.
Not Safe: Codifab Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Not Safe: Codifab Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Seek medical advice from your doctor: It is not known whether Codifab Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Caution Advised: Codifab Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Codifab Tablet may be needed. Doctor consultation is advised.
Caution Advised: Codifab Tablet should be used with caution in patients with severe liver disease. Dose adjustment of Codifab Tablet may be needed. Doctor consultation is advised.
What if I forget to take it?
If a dose of Codifab Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
204, 2nd Floor, G-Corp Tech Park, Kasarvadavali, Near Hypercity, Ghodbandar Road, Thane (West) - 400615. ,Maharashtra, India
References
Favipiravir. Tokyo, Japan: Toyama Chemical Co., Ltd.; 2017. (online) Available from
Abdelnabi R, Morais ATS, Leyssen P, et al. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. J Virol. 2017;91(12):e00487-17. (online) Available from
DrugBank. Favipiravir
MaHTAS COVID-19 Rapid Evidence Updates. Favipiravir (AVIGAN®) to Treat Coronavirus Disease 2019 (COVID-19)
OpIndia. Glenmark starts phase-3 clinical trial for potential coronavirus drug Favipiravir in India. 12 May, 2020. (online) Available from
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
